Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by inthnoon Nov 07, 2001 11:56pm

1323 Views

Post# 4381765

RE: "advancing discussions"?

BIOEYE; Thanks for the clarification.I did find it interesting though, that during my conversation with onc that they stated that phase 1 had to be "released" before actual therapy of phase 2 prostate. Is it possible that they meant that phase 1 had to be "completed" and approval by hc before commencing? Thanks for your comments and input as always.This bb and I appreciate the time and effort that you put in your research. Inthno

Bullboard Posts

Mullen Group: Navigates market challenges towards success